

Ophthalmoplegia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/OCEC25813E46EN.html>

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: OCEC25813E46EN

Abstracts

The 7 major ophthalmoplegia markets are expected to exhibit a CAGR of 6.22% during 2024-2034.

The ophthalmoplegia market has been comprehensively analyzed in IMARC's new report titled "Ophthalmoplegia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ophthalmoplegia is a medical condition characterized by weakness or paralysis of the muscles responsible for eye movements. Depending on the location of the affected muscles, this disease can be categorized as either external or internal. External ophthalmoplegia refers to an impairment of the extraocular muscles, most commonly those that regulate eye motion. Internal ophthalmoplegia, on the other hand, involves the muscles within the eye itself, which are responsible for constriction and the size of the pupil. Individuals suffering from ophthalmoplegia may experience difficulty moving their eyes in certain directions, double vision, droopy eyelids, blurred vision, problems with focusing, etc. The diagnosis of the illness usually requires a comprehensive evaluation of medical history, underlying indications, and a physical examination. The healthcare provider will also perform neurological tests involving the nerves that control eye movements to check for any signs of weakness or abnormal reflexes. Numerous imaging studies, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, are further required to visualize the structures of the brain, eye sockets, and surrounding tissues.

The increasing cases of head injuries or trauma to the eye structures, which can directly damage the cranial nerves or their pathways, are primarily driving the ophthalmoplegia market. In addition to this, the rising prevalence of autoimmune conditions, like thyroid eye disease, that involve inflammation of the eye muscles or surrounding tissues is also

creating a positive outlook for the market. Moreover, the widespread adoption of botulinum toxin injections for treating the ailment on account of their numerous advantages, such as better alignment and reduced double vision, is further bolstering the market growth. Apart from this, the escalating application of immunosuppressive therapy, since it suppresses the body's immune response to control inflammation and prevents the worsening of muscle damage among patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of decompression surgery, which aims to relieve the compression or entrapment of the affected nerves and allow for restoration of eye function, thereby enhancing the quality of life, is expected to drive the ophthalmoplegia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the ophthalmoplegia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for ophthalmoplegia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ophthalmoplegia market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the ophthalmoplegia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the ophthalmoplegia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current ophthalmoplegia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the ophthalmoplegia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the ophthalmoplegia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the ophthalmoplegia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of ophthalmoplegia across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of ophthalmoplegia by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of ophthalmoplegia by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with ophthalmoplegia across the seven major markets?

What is the size of the ophthalmoplegia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of ophthalmoplegia?

What will be the growth rate of patients across the seven major markets?

Ophthalmoplegia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for ophthalmoplegia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ophthalmoplegia market?

What are the key regulatory events related to the ophthalmoplegia market?

What is the structure of clinical trial landscape by status related to the ophthalmoplegia market?

What is the structure of clinical trial landscape by phase related to the ophthalmoplegia market?

What is the structure of clinical trial landscape by route of administration related to the ophthalmoplegia market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 OPHTHALMOPLEGIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 OPHTHALMOPLEGIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 OPHTHALMOPLEGIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 OPHTHALMOPLEGIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 OPHTHALMOPLEGIA - UNMET NEEDS

10 OPHTHALMOPLEGIA - KEY ENDPOINTS OF TREATMENT

11 OPHTHALMOPLEGIA - MARKETED PRODUCTS

- 11.1 List of Ophthalmoplegia Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 OPHTHALMOPLEGIA - PIPELINE DRUGS

12.1 List of Ophthalmoplegia Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. OPHTHALMOPLEGIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. OPHTHALMOPLEGIA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 OPHTHALMOPLEGIA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Ophthalmoplegia - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Ophthalmoplegia - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Ophthalmoplegia - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Ophthalmoplegia - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Ophthalmoplegia - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Ophthalmoplegia - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Ophthalmoplegia - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Ophthalmoplegia - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Ophthalmoplegia - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Ophthalmoplegia - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Ophthalmoplegia - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Ophthalmoplegia - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Ophthalmoplegia - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Ophthalmoplegia - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Ophthalmoplegia - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Ophthalmoplegia - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Ophthalmoplegia - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Ophthalmoplegia - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Ophthalmoplegia - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Ophthalmoplegia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Ophthalmoplegia - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Ophthalmoplegia - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Ophthalmoplegia - Access and Reimbursement Overview

16 OPHTHALMOPLEGIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 OPHTHALMOPLEGIA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 OPHTHALMOPLEGIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Ophthalmoplegia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/OCEC25813E46EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OCEC25813E46EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

